Citations

Clear

3030 citation(s) found for "Susan, M".

Financial Management of a Large Multisite Randomized Clinical Trial
Sheffet, Alice J., Flaxman, Linda, Tom, MeeLee , Hughes, Susan , Longbottom, Mary, Howard, Virginia J. , Marler, John R., Brott, Thomas G. , Investigators, for the CREST, Investigators, for the CREST, Howard, Virginia J

Mayo Clinic

International Journal of Stroke | March 25, 2014 | Volume: 9 | Issue: 6 | Pages: 811-813

10.1111/ijs.12259 | PMID 24661748 Get It

Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) received five years' funding ($21 112 866) from the National Institutes of Health to compare carotid stenting to surgery for stroke prevention in 2500 randomized participants at 40 sites. Aims Herein we evaluate the change in the CREST budget from a fixed to variable-cost model and recommend strategies for the financial management of large-scale clinical trials. Methods Projections of the original grant's fixed-cost model were compared to the actual costs of the revised variable-cost model. The original grant's fixed-cost budget included salaries, fringe benefits, and other direct and indirect costs. For the variable-cost model, the costs were actual payments to the clinical sites and core centers based upon actual trial enrollment. We compared annual direct and indirect costs and per-patient cost for both the fixed and variable models. Differences between clinical site and core center expenditures were also calculated. Results Using a variable-cost budget for clinical sites, funding was extended by no-cost extension from five to eight years. Randomizing sites tripled from 34 to 109. Of the 2500 targeted sample size, 138 (5·5%) were randomized during the first five years and 1387(55·5%) during the no-cost extension. The actual per-patient costs of the variable model were 9% ($13 845) of the projected per-patient costs ($152 992) of the fixed model. Conclusions Performance-based budgets conserve funding, promote compliance, and allow for additional sites at modest additional cost. Costs of large-scale clinical trials can thus be reduced through effective management without compromising scientific integrity.
A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study
Fouladi, Maryam , Perentesis, John P. , Phillips, Christine L. , Leary, Sarah , McGovern, Renee M., Ingle, Ashish M., Ahern, Charlotte H., Ames, Matthew M. , Houghton, Peter J. , Doyle, L. Austin, Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Leary, Sarah

Mayo Clinic

Pediatric Blood & Cancer | March 25, 2014 | Volume: 61 | Issue: 7 | Pages: 1246-1251

10.1002/pbc.25023 | PMID 24664955 Get It

BackgroundWe report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose‐limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK‐2206, an AKT inhibitor, in children with refractory or recurrent malignancies.ProcedureMK‐2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28‐day cycle. Dose escalations in increments of ∼30% were independently made in each part using the rolling‐six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT‐cell signaling pathway in pre and post‐therapy in PBMC and in tumors at diagnosis or recurrence.ResultsFifty patients (26 males, median age 12.6 years [range, 3.1–21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n = 23; Schedule 2, n = 17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28 mg/m2; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45 mg/m2; and grade 3 rash in 3/6 patients at dose level 4 (58 mg/m2). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90 mg/m2; grade 3 rash in 1/6 patients at 120 mg/m2; and grade 3 rash in 2/6 patients at 155 mg/m2.ConclusionsThe recommended pediatric phase 2 dose of MK‐2206 is 45 mg/m2/dose every other day or 120 mg/m2/dose weekly. PK appeared linear over the dose range studied. Pediatr Blood Cancer 2014;61:1246–1251. © 2014 Wiley Periodicals, Inc.
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
Investigators, The Parkinson Study Group QE3, Beal, M. Flint, Oakes, David , Shoulson, Ira , Henchcliffe, Claire , Galpern, Wendy R., Haas, Richard , Juncos, Jorge L., Nutt, John G. , Voss, Tiffini, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark, Griebner, Brian, Watts, Arthur, Gao, Shan , Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie , Sia, Cherissa, Jog, Mandar , Sultana, Munira , Kurlan, Roger, Richard, Irene Hegeman, Deeley, Cheryl, Waters, Cheryl , Figueroa, Angel, Arkun, Ani, Brodsky, Matthew , Ondo, William G. , Hunter, Christine , Jimenez‐Shahed, Joohi , Palao, Alicia, Miyasaki, Janis M. , So, Julie , Tetrud, James W., Reys, Liza, Singer, Carlos , Blenke, Anita, Russell, David , Cotto, Candace, Lannon, Margaret C., Drasby, Edward, Kumar, Rajeev , Subramanian, Thyagarajan , Ford, Donna Stuppy, Grimes, David A. , Côté, Diane , Conway, Jennifer, Siderowf, Andrew , Evatt, Marian L., Sommerfeld, Barbara, Lieberman, Abraham, Okun, Michael S. , Rodriguez, Ramon L. , Merritt, Stacy, Swartz, Camille, Martin, W. R. Wayne , King, Pamela, Stover, Natividad , Guthrie, Stephanie, Watts, Ray L., Fernandez, Hubert H. , Winters, Adrienna, Dawson, Ted M. , Dunlop, Becky, Feigin, Andrew, Shannon, Barbara , Nirenberg, Melissa J. , Ogg, Mattson , Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen , Bódis-Wollner, Iván , Glazman, Sofya, Mayer, Thomas A. , Hauser, Robert A. , Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Farrow, Buff, Prakash, Rajan , Litvan, Irene , Robinson, Annette, Sahay, Alok , Gartner, Maureen, Markind, Samuel, Pelikan, Melisa, Hartlein, Johanna M, Molho, Eric , Evans, Sharon, Duffy, Amy, Lind, Marlene, Elmer, Lawrence , Davis, Kathy, Spears, Julia, Leehey, Maureen A. , Hermanowicz, Neal , Niswonger, Shari, Shill, Holly A. , Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Fontaine, Deborah, Zadikoff, Cindy , Williams, Karen, Blindauer, Karen, Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark, Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K. , Kraics, Lauren, Silver, Althea, Boyd, James T. , Hamill, Robert W., Ingvoldstad, Christopher T., Young, Jennifer , Thomas, Karen, Kostyk, Sandra K. , Wojcieszek, Joanne, Pfeiffer, Ronald F. , Panisset, Michel , Beland, Monica, Reich, Stephen G. , Cines, Michelle, Zappala, Nancy, Rivest, J., Zweig, Richard M., Lumina, L. Pepper, Hilliard, Colette Lynn, Grill, Stephen , Kellermann, Marye, Tuite, Paul , Rolandelli, Susan, Kang, Un Jung , Young, Joan, Rao, Jayaraman, Cook, Maureen, Severt, Lawrence, Boyar, Karyn, Scott, Ingrid U. , Investigators, The Parkinson Study Group QE3, Beal, M. Flint , Agarwal, Pinky , Cole, Linda C. , Smith, Katharine , Friedman, Joseph H. , Zhang, Lin , Ahmed, Anwar E. , Mari, Zoltan K. , Pahwa, Rajesh , Sethi, Kapil D. , Hinson, Vanessa K. , Perlmutter, Joel S. , Adler, Charles H. , Wilson, Stephanie M. G. , Song, David , Williams, Karen, Uc, Ergun Y., Okun, Michael S , Litvan, Irene , Hauser, Robert A , Jimenez-Shahed, Joohi

Mayo Clinic

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 | PMID 24664227 Get It

Upper Extremity Orthoses Use in Amyotrophic Lateral Sclerosis/Motor Neuron Disease: Three Case Reports
Ivy, Cindy, Materi, Miranda M., Ivy, Cindy C, Smith, Susan M, Smith, Susan M.

Mayo Clinic

HAND | March 18, 2014 | Volume: 9 | Issue: 4 | Pages: 543-550

10.1007/s11552-014-9626-x | PMID 25414620 Get It

Background Central to the armamentarium of a hand therapist is evaluation for successful orthotic use. Orthoses can have a profound effect on quality of life in persons with amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The purposes of orthoses are to decrease the effects of muscle imbalance, provide assistance in performance of activities of daily living (ADLs), prevent joint contracture, and relieve pain. There are few published accounts on the usefulness of orthoses and ALS. The purpose of this paper is to expand the body of literature by describing three successful cases. Methods Three cases illustrate effects on weakened proximal muscles, wrist extensors, thenar musculature, and intrinsic muscles. The primary outcome measure is patient report, but functional rating scales, goniometry, quality of life scores, and pinch strength when obtainable are described. Results Due to the progressive nature of the disease, outcome measures can be inconclusive. Patient report of increased life satisfaction and ability to participate in daily life is the critical outcome in these case examples. In all cases, satisfaction increased. Some of the stated changes include the following: ability to manipulate objects, grip, eat, wipe face, hold phone, use iPad®, and adjust hat. Conclusions Upper extremity orthotic use can be a beneficial adjunct contributing to the quality of life for individuals with ALS/MND. We have observed positive responses in pain control, contracture management, functional positioning, and increased independence with the use of orthoses. Designing appropriate means of studying effects of orthosis intervention is deficient in the current scientific literature.
Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma
Gustafson, Heather L., Goldman, Bryan, Spier, Catherine, Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Persky, Daniel O. , Miller, Thomas P. , Fisher, Richard I., Briehl, Margaret M., Yao, Song , Lee, Kristy , LeBlanc, Michael , Rimsza, Lisa M. , Habermann, Thomas M. , Slager, Susan L. , Ambrosone, Christine B. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

American Journal of Hematology | March 14, 2014 | Volume: 89 | Issue: 6 | Pages: 639-645

10.1002/ajh.23709 | PMID 24633940 Get It

Variable survival outcomes are seen following treatment for aggressive non‐Hodgkin lymphoma (NHL). This study examined whether outcomes for aggressive B‐cell NHL are associated with single nucleotide polymorphisms (SNPs) in oxidative stress‐related genes, which can alter drug metabolism and immune responses. Genotypes for 53 SNPs in 29 genes were determined for 337 patients given anthracycline‐based therapies. Their associations with progression‐free survival (PFS) and overall survival (OS) were estimated by Cox proportional hazard regression; associations with hematologic toxicity were estimated by logistic regression. To validate the findings, the top three SNPs were tested in an independent cohort of 572 DLBCL patients. The top SNPs associated with PFS in the discovery cohort were the rare homozygotes for MPO rs2243828 (hazard ratio [HR] = 1.87, 95% confidence interval [CI] = 1.14–3.06, P = 0.013), AKR1C3 rs10508293 (HR = 2.09, 95% CI = 1.28–3.41, P = 0.0032) and NCF4 rs1883112 (HR = 0.66, 95% CI = 0.43–1.02, P = 0.06). The association of the NCF4 SNP with PFS was replicated in the validation dataset (HR = 0.66, 95% CI = 0.44–1.01, P = 0.05) and the meta‐analysis was significant (HR = 0.66, 95% CI = 0.49–0.89, P < 0.01). The association of the MPO SNP was attenuated in the validation dataset, while the meta‐analysis remained significant (HR = 1.64, 95% CI = 1.12–2.41). These two SNPs showed similar trends with OS in the meta‐analysis (for NCF4, HR = 0.72, 95% CI = 0.51–1.02, P = 0.07 and for MPO, HR = 2.06, 95% CI = 1.36–3.12, P < 0.01). In addition, patients with the rare homozygote of the NCF4 SNP had an increased risk of hematologic toxicity. We concluded that genetic variations in NCF4 may contribute to treatment outcomes for patients with aggressive NHL. Am. J. Hematol. 89:639–645, 2014. © 2014 Wiley Periodicals, Inc.
Associations Among Fluid Intake, Cognitive Function, and Length of Stay in Psychogeriatric Inpatients
Archer, Sarah J., Barna, Amy E., Holper, Roxanna M., Forsyth, Diane McNally, Ellenbecker, Susan M., Smith, Linda K., Clobes, Jane E., Malone, Chris, Meiers, Sonja J. , Malone, Christopher B., Lapid, Maria I.

Mayo Clinic

Perspectives in Psychiatric Care | March 8, 2014 | Volume: 51 | Issue: 1 | Pages: 52-56

10.1111/ppc.12065 | PMID 24605762 Get It

Preliminary Comparison of Laparoendoscopic Single-Site Surgery Instrumentation With Novice Surgical Interns: How Usability Testing Can Reveal Human Factors Issues Prior to Errors in the Operating Room1
Lowndes, Bethany R. , Farley, David R. , Hallbeck, M. Susan , McCrory, Bernadette , LaGrange, Chad A. , Hallbeck, M Susan

Mayo Clinic

Journal of Medical Devices | March 6, 2014 | Volume: 8 | Issue: 2 | Pages: No page available

10.1115/1.4027063 Get It

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Maurer, Matthew J. , Ghesquières, Hervé , Jais, Jean‐Philippe, Haïoun, Corinne , Thompson, Carrie A. , Delarue, Richard, Micallef, Ivana N. , Peyrade, Frédéric, Macon, William R. , Molina, Thierry Jo , Ketterer, Nicolas , Syrbu, Sergei , Fitoussi, Olivier , Kurtin, Paul J. , Allmer, Cristine, Nicolas‐Virelizier, Emmanuelle , Link, Brian K. , Salles, Gilles , Tilly, Hervé , Cerhan, James R. , Jaïs, Jean‐Philippe , Witzig, Thomas E. , Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Salles, Gilles A , Syrbu, Sergei

Mayo Clinic

Journal of Clinical Oncology | February 19, 2014 | Volume: 32 | Issue: 10 | Pages: 1066-1073

10.1200/jco.2013.51.5866 | PMID 24550425 Get It

Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference population data. Patients and Methods Patients with newly diagnosed DLBCL treated with immunochemotherapy were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource (MER) and the North Central Cancer Treatment Group NCCTG-N0489 clinical trial from 2002 to 2009. Patient outcomes were evaluated at diagnosis and in the subsets of patients achieving event-free status at 12 months (EFS12) and 24 months (EFS24) from diagnosis. Overall survival was compared with age- and sex-matched population data. Results were replicated in an external validation cohort from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Lymphome Non Hodgkinien 2003 (LNH2003) program and a registry based in Lyon, France. Results In all, 767 patients with newly diagnosed DLBCL who had a median age of 63 years were enrolled onto the MER and NCCTG studies. At a median follow-up of 60 months (range, 8 to 116 months), 299 patients had an event and 210 patients had died. Patients achieving EFS24 had an overall survival equivalent to that of the age- and sex-matched general population (standardized mortality ratio [SMR], 1.18; P = .25). This result was confirmed in 820 patients from the GELA study and registry in Lyon (SMR, 1.09; P = .71). Simulation studies showed that EFS24 has comparable power to continuous EFS when evaluating clinical trials in DLBCL. Conclusion Patients with DLBCL who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. EFS24 will be useful in patient counseling and should be considered as an end point for future studies of newly diagnosed DLBCL.
Intervention to Promote Physician Well-being, Job Satisfaction, and Professionalism
Rabatin, Jeff T., Call, Tim G., Davidson, John H., Multari, Adamarie, Romanski, Susan A., Hellyer, Joan M. Henriksen, Sloan, Jeff A. , Dyrbye, Liselotte N. , West, Colin P. , Call, Timothy G., Shanafelt, Tait D.

Mayo Clinic

JAMA Internal Medicine | February 10, 2014 | Volume: 174 | Issue: 4 | Pages: 527

10.1001/jamainternmed.2013.14387 | PMID 24515493 Get It

Cultivating and Nurturing a Successful Organizational Stressmanagement Program: Mission of Unlimited Possibilities
Eley, Christine L., Harris, Katherine , Hudak, Barbara, Hulvey, Lynne E., Launder, Susan

Mayo Clinic

Global Advances in Health and Medicine | February 5, 2014 | Volume: 3 | Issue: 1_suppl | Pages: No page available

10.7453/gahmj.2014.bpa08 Get It